Last reviewed · How we verify
San Huang Xie Jin Tang
San Huang Xie Jin Tang is a Small molecule drug developed by Committee on Chinese Medicine and Pharmacy. It is currently in Phase 2 development.
At a glance
| Generic name | San Huang Xie Jin Tang |
|---|---|
| Sponsor | Committee on Chinese Medicine and Pharmacy |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- San Huang Xie Jin Tang CI brief — competitive landscape report
- San Huang Xie Jin Tang updates RSS · CI watch RSS
- Committee on Chinese Medicine and Pharmacy portfolio CI
Frequently asked questions about San Huang Xie Jin Tang
What is San Huang Xie Jin Tang?
San Huang Xie Jin Tang is a Small molecule drug developed by Committee on Chinese Medicine and Pharmacy.
Who makes San Huang Xie Jin Tang?
San Huang Xie Jin Tang is developed by Committee on Chinese Medicine and Pharmacy (see full Committee on Chinese Medicine and Pharmacy pipeline at /company/committee-on-chinese-medicine-and-pharmacy).
What development phase is San Huang Xie Jin Tang in?
San Huang Xie Jin Tang is in Phase 2.